Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Annals of Neurology

• Publication date

  1994-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/ana.410360112PMID 8024262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Irreversible motor impairment in young addicts – ephedrone, manganism or both?

  2007cited by this paper
• Neuronal loss in the basal nucleus of meynert in progressive supranuclear palsy

  2004cited by this paper
• Transient impairment of recognition memory following ibotenic-acid lesions of the basal forebrain in macaques

  2004cited by this paper
• Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man

  2004cited by this paper
• [The thalamic changes in progressive supranuclear palsy].

  1992cited by this paper
• The auditory startle response in the Steele-Richardson-Olszewski syndrome and Parkinson's disease.

  1992cited by this paper
• Progressive supranuclear palsy : clinical and research approaches

  1992cited by this paper
• Progressive supranuclear palsy

  1991cited by this paper
• Mesencephalic cholinergic nuclei in progressive supranuclear palsy

  1991cited by this paper
• Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy.

  1991cited by this paper
• The Clinical Validity of the Mattis Dementia Rating Scale in Staging Alzheimer's Dementia

  1991cited by this paper
• Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.

  1991cited by this paper
• Frontal lobe function in progressive supranuclear palsy.

  1990cited by this paper
• Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.

  1990cited by this paper
• Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases.

  1989cited by this paper
• Physostigmine treatment of progressive supranuclear palsy

  1989cited by this paper
• Memory impairment in patients with progressive supranuclear palsy.

  1989cited by this paper
• Reductions in acetylcholine and nicotine binding in several degenerative diseases.

  1988cited by this paper
• Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale

  1987cited by this paper
• Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy.

  1987cited by this paper
• A comparison of the effects of two inhibitors on brain cholinesterase.

  1987cited by this paper
• Rigidity and dorsiflexion of the neck in progressive supranuclear palsy and the interstitial nucleus of Cajal.

  1987cited by this paper
• Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.

  1987cited by this paper
• Progressive supranuclear palsy: Relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers

  1985cited by this paper
• Progressive supranuclear palsy: Postmortem chemical analysis

  1985cited by this paper
• Dopaminergic and cholinergic lesions in progressive supranuclear palsy

  1985cited by this paper
• Acute effects of scopolamine in Huntington's disease.

  1983cited by this paper
• Effect of unilateral orchidectomy on plasma FSH concentration: evidence for a direct neural connection between testes and CNS.

  1983cited by this paper
• Evaluating storage, retention, and retrieval in disordered memory and learning

  1974cited by this paper
• The central effects of scopolamine in man.

  1971cited by this paper
• Cholinergic-anticholinergic antagonism in parkinsonism.

  1967cited by this paper
• Neurochemistry.

  1960cited by this paper
• NEUROPATHOLOGY

  1954cited by this paper
• Effects of chronic lesions in central cephalic brain stem of monkeys.

  1952cited by this paper
• Effect upon the EEG of acute injury to the brain stem activating system.

  1949cited by this paper
• Clinical Diagnosis

  1890cited by this paper

• The validity and reliability of the Test of Memory Strategies among Italian healthy adults

  2022cites this paper
• Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders

  2021cites this paper
• Four-Repeat Tauopathies: Current Management and Future Treatments

  2020cites this paper
• Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementia

  2020cites this paper
• Progressive supranuclear palsy.

  2019cites this paper
• Neurotransmitter deficits from frontotemporal lobar degeneration

  2018cites this paper
• No Neuromuscular Side-Effects of Scopolamine in Sensorimotor Control and Force-Generating Capacity Among Parabolic Fliers

  2016cites this paper
• No Neuromuscular Side-Effects of Scopolamine in Sensorimotor Control and Force-Generating Capacity Among Parabolic Fliers

  2016cites this paper
• Progressive Supranuclear Palsy

  2014cites this paper
• Chapter 9 – Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders

  2011cites this paper
• Progressive supranuclear palsy and corticobasal degeneration.

  2011cites this paper
• Milestones in atypical and secondary Parkinsonisms

  2011cites this paper
• Pedunculopontine nucleus deep brain stimulation in Parkinson’s disease

  2011cites this paper
• Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia.

  2010cites this paper
• History of falls in Parkinson disease is associated with reduced cholinergic activity

  2009cites this paper
• Current and future therapeutic approaches in progressive supranuclear palsy.

  2008cites this paper
• Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors

  2007cites this paper
• Antero‐ventral internal pallidum stimulation improves behavioral disorders in Lesch–Nyhan disease

  2007cites this paper
• Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes

  2007cites this paper
• Progressive supranuclear palsy.

  2007cites this paper
• Current and future treatments in progressive supranuclear palsy

  2006cites this paper
• Klinik und Therapie der Multisystem- atrophie und progressiven supra- nukleären Paralyse

  2005cites this paper
• Toward future therapies in progressive supranuclear palsy

  2005cites this paper
• Neurodegenerative Diseases: Progressive supranuclear palsy

  2005cites this paper
• Chapter 11 - Progressive Supranuclear Palsy and Corticobasal Degeneration

  2005cites this paper
• Gait Disorders : Evaluation and Management

  2005cites this paper
• Treatment of Axial Mobility Deficits in Movement Disorders

  2005cites this paper
• Current and Future Therapeutic Approaches

  2005cites this paper
• Treatment of progressive supranuclear palsy and corticobasal degeneration

  2005cites this paper
• Cholinergic systems in progressive supranuclear palsy.

  2004cites this paper
• Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration

  2003influential citation
• Progressive supranuclear palsy as a cause of balance disorders.

  2003cites this paper
• Chapter 75 – Atypical Parkinsonism

  2003cites this paper
• Parkinson's disease and related parkinsonian syndromes

  2003cites this paper
• Cerebrolysin in Steel: Richardson-Olszewski Syndrome

  2002cites this paper
• Diagnosis and Management of Progressive Supranuclear Palsy

  2001cites this paper
• Donepezil in the treatment of progressive supranuclear palsy

  2001cites this paper
• Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

  2001cites this paper
• Lumping and splitting the Parkinson Plus syndromes: dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal ganglionic degeneration.

  2001cites this paper
• Progressive supranuclear palsy

  2001cites this paper
• Research goals in progressive supranuclear palsy

  2000cites this paper
• Progressive supranuclear palsy in the molecular age.

  2000cites this paper
• Progressive Supranuclear Palsy

  2000cites this paper
• Progressive supranuclear palsy in the molecular age

  2000cites this paper
• Progressive supranuclear palsy.

  1999cites this paper
• Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy

  1999cites this paper
• Effects of Physostigmine on Swallowing and Oral Motor Functions in Patients with Progressive Supranuclear Palsy: A Pilot Study

  1999cites this paper
• Progressive supranuclear palsy (Steele-Richardson-Olszewski disease)

  1999cites this paper
• Apolipoprotein E4 (epsilon) allele does not affect the onset or symptom severity in progressive supranuclear palsy.

  1998cites this paper
• Review article Progressive supranuclear palsy revisited

  1998cites this paper
• PROGRESSIVE SUPRANUCLEAR PALSY: STARING INTO THE PAST, MOVING INTO THE FUTURE

  1998cites this paper
• Pharmacological therapy in progressive supranuclear palsy.

  1998cites this paper
• Cognition-enhancing drugs in dementia: a guide to the near future.

  1997cites this paper
• Progressive supranuclear palsy and corticobasal degeneration.

  1997cites this paper
• Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?

  1996cites this paper
• Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?

  1995cites this paper